The Business Research Company’s report on the Lower Respiratory Tract Therapeutics Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the key drivers behind the lower respiratory tract therapeutics market’s growth in recent years?
The rising prevalence of respiratory diseases will boost the lower respiratory tract therapeutics market going forward. Respiratory diseases refer to medical conditions that affect the respiratory system, which includes the lungs, bronchi, trachea, larynx, pharynx, and nasal passages. Lower respiratory tract therapeutics is primarily used for the early detection and diagnosis of respiratory conditions, which can lead to earlier treatment and management. This can help prevent the progression of the disease and is also essential for controlling the spread of infectious respiratory diseases and reducing the risk of complications. For instance, in September 2022, according to the data from the NCD Alliance, a Switzerland-based civil society organization, lung cancer was the leading cause of cancer deaths worldwide, with 2.2 million new cases and 1.8 million fatalities anticipated year on year. Further, chronic respiratory disorders impacted 550 million adults globally, and 4.2 million people died, or 7 %. Therefore, the rising prevalence of respiratory diseases will drive the lower respiratory tract therapeutics market.
Access Your Free Sample of the Global Lower Respiratory Tract Therapeutics Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12591&type=smp
How does the future projection of the lower respiratory tract therapeutics market size compare to its historical growth?
The lower respiratory tract therapeutics market size has grown strongly in recent years. It will grow from $36.03 billion in 2024 to $38.98 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to antibiotic discoveries, vaccination programs, smoking cessation campaigns, advancements in inhalation therapy, healthcare infrastructure growth
The lower respiratory tract therapeutics market size is expected to see strong growth in the next few years. It will grow to $53.47 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to rising air pollution levels, aging population, antimicrobial resistance, environmental factors. Major trends in the forecast period include precision medicine approaches, technological innovation, biologic therapies, telehealth in respiratory care, personalized inhalation devices.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12591&type=smp
Which key players are shaping the future of the lower respiratory tract therapeutics market?
Major companies operating in the lower respiratory tract therapeutics market include Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Menarini Group, Chiesi Farmaceutici S.p.A., Cipla Limited, Mundipharma International Limited, Orion Corporation, Sunovion Pharmaceuticals Inc., Innoviva Inc., Insmed Incorporated, Vectura Group plc, Theravance Biopharma Inc., Verona Pharma plc, Circassia Pharmaceuticals plc
What trends will propel the growth and evolution of the lower respiratory tract therapeutics market?
Product innovations are a key trend in the lower respiratory tract therapeutics market. Major companies operating in the lower respiratory tract therapeutics market are introducing innovative products to strengthen their position in the market. For instance, in November 2022, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, and Sanofi S.A., a France-based pharmaceutical company, launched Beyfortus to prevent lower respiratory tract disease in newborns and infants. The European Union (E.U) has approved this medicine to prevent respiratory syncytial virus (RSV) and lower respiratory tract illness in newborns and babies throughout the initial RSV season. It is the first single-dose RSV passive vaccination for the general newborn population, including those born healthy, at term or prematurely, or with special medical issues.
Which regions are expected to become dominant players in the lower respiratory tract therapeutics market?
North America was the largest region in the lower respiratory tract therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lower respiratory tract therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
What are the emerging key segments in the lower respiratory tract therapeutics market, and how are they evolving?
The lower respiratory tract therapeutics market covered in this report is segmented –
1) By Disease Type: Asthma, Chronic Obstructive Pulmonary Disease, Pneumonia, Tuberculosis, Bronchitis, Other Diseases
2) By Drug Class: Antibiotics, Non-Steroidal Anti-Inflammatory Drug, Cough Suppressant, Nasal Decongestant, Other Drug Classes
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Asthma: Allergic Asthma, Non-allergic Asthma
2) By Chronic Obstructive Pulmonary Disease (COPD): Chronic Bronchitis, Emphysema
3) By Pneumonia: Bacterial Pneumonia, Viral Pneumonia
4) By Tuberculosis: Drug-sensitive Tuberculosis, Drug-resistant Tuberculosis
5) By Bronchitis: Acute Bronchitis, Chronic Bronchitis
6) By Other Diseases: Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12591
What defines the structure and scope of the lower respiratory tract therapeutics market?
The lower respiratory tract refers to the portion of the respiratory system exchanging gases, where oxygen is taken in, and carbon dioxide is expelled. Lower respiratory tract therapeutics refers to the branch of medical science and clinical practice that focuses on diagnosing, treating, and managing diseases and disorders affecting the lower respiratory tract. These therapeutics improve the quality of life and overall health outcomes for individuals with lower respiratory tract disorders.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
